Shield Therapeutics Past Earnings Performance
Past criteria checks 0/6
Shield Therapeutics's earnings have been declining at an average annual rate of -4.4%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 51.4% per year.
Key information
-4.39%
Earnings growth rate
26.49%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.12% |
| Revenue growth rate | 51.44% |
| Return on equity | n/a |
| Net Margin | -35.52% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Narrative Update • Jun 05
STX: Pediatric And Japan Trial Milestones Will Drive Future Earnings Upside
Shield Therapeutics' analyst price target is now set at £0.14. Analysts attribute this level to unchanged fair value, discount rate and P/E assumptions, combined with modest adjustments to revenue growth and profit margin forecasts.Narrative Update • May 21
STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside
Shield Therapeutics’ latest analyst price target has been set at £0.14, with analysts attributing this unchanged fair value to a slightly adjusted discount rate, modestly revised revenue growth and profit margin assumptions, and a recalibrated future P/E multiple. What's in the News MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II exploratory clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension.Narrative Update • May 04
STX: Pediatric And Asia Expansion Will Drive Future Earnings Upside
Analysts have adjusted their price target on Shield Therapeutics to £0.14 per share, with the change linked to updated assumptions that maintain the fair value level while recalibrating revenue growth, profit margin and future P/E expectations. What's in the News Partner MEDLEAP Pharma enrolled the first patient in a Phase II clinical trial in Japan testing ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency (Product-Related Announcement).Narrative Update • Apr 18
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Analysis Article • Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
It's been a good week for Shield Therapeutics plc ( LON:STX ) shareholders, because the company has just released its...Narrative Update • Apr 03
STX: Pediatric And China Approvals Will Expand Future Earnings Power
Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.
Narrative Update • Mar 20
STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside
Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.Narrative Update • Mar 06
STX: Pediatric Expansion And China Filing Will Redefine Earnings Power
Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).Narrative Update • Feb 19
STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential
Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).Narrative Update • Feb 05
STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside
Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).Narrative Update • Jan 22
STX: Pediatric Expansion And New Market Approvals Will Support Future Upside
Analysts have lifted their price target on Shield Therapeutics from £0.16 to about £0.17, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What’s in the News US FDA grants priority review approval to extend ACCRUFeR’s indication to adolescents, covering iron deficiency treatment in patients 10 years and older, backed by positive Phase 3 pediatric trial data (FORTIS/ST10-01-305) (Key Developments).Narrative Update • Jan 07
STX: Expanded Pediatric And Global Approvals Will Support Future Upside
Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.Narrative Update • Dec 18
STX: Future US Label Expansion Could Still Leave Shares Vulnerable
Analysts have raised their price target for Shield Therapeutics from 0.03 dollars to 0.10 dollars, citing slightly stronger long term revenue growth expectations, while applying a higher discount rate and more conservative profit margin and valuation multiples. What's in the News Presentation of pediatric FORTIS PK sub study at the American Society of Hematology conference in December 2025 showed ferric maltol is well absorbed across pediatric age groups, with maltol rapidly metabolized and excreted, supporting its suitability for iron replacement in children and adolescents (company announcement).Narrative Update • Dec 04
STX: New Regulatory Approvals And Pediatric Data Will Drive Future Upside
Analysts have modestly increased their price target on Shield Therapeutics, citing slightly stronger projected revenue growth, a marginally lower profit margin, and a modestly higher future price-to-earnings multiple. What's in the News The Korean Ministry of Food and Drug Safety granted regulatory approval for ACCRUFeR (ferric maltol) in adults with iron deficiency, opening a new commercial market and triggering eligibility for milestones and royalties (company announcement).Analysis Article • Nov 25
Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in the United Kingdom...Narrative Update • Nov 20
STX: FDA Priority Review and Regulatory Approvals Will Drive Significant Upside
Analysts have modestly raised their price target for Shield Therapeutics from $0.16 to $0.16 per share. This change reflects updated assumptions around discount rates and profit margins, while maintaining a cautiously optimistic outlook.Narrative Update • Nov 06
STX: Upcoming FDA Decision Will Drive Confidence After Positive Pediatric Results
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation. What's in the News Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference.Narrative Update • Oct 22
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Narrative Update on Shield Therapeutics: Analyst Price Target Revision Analysts have maintained their price target for Shield Therapeutics at £0.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.Narrative Update • Oct 08
Global Aging Trends And Early Detection Will Unlock Markets
Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts. What's in the News Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).Analysis Article • Aug 23
The Market Lifts Shield Therapeutics plc (LON:STX) Shares 76% But It Can Do More
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 76% in...New Narrative • Aug 03
Global Aging Trends And Early Detection Will Unlock Markets
An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product.Analysis Article • Jun 28
Shield Therapeutics plc (LON:STX) Soars 27% But It's A Story Of Risk Vs Reward
Shield Therapeutics plc ( LON:STX ) shares have had a really impressive month, gaining 27% after a shaky period...Analysis Article • Feb 06
Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Shield Therapeutics plc ( LON:STX ) shareholders have had their patience rewarded with a 26% share price jump in the...Analysis Article • Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Shield Therapeutics plc ( LON:STX ) share price has softened a substantial 28% over the previous 30 days, handing...Analysis Article • Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 44% in...Analysis Article • Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Key Insights Shield Therapeutics will host its Annual General Meeting on 20th of June CEO Greg Madison's total...Analysis Article • May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
Shield Therapeutics plc ( LON:STX ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Shield Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 50 | -18 | 32 | 2 |
| 30 Sep 25 | 46 | -19 | 32 | 2 |
| 30 Jun 25 | 41 | -21 | 33 | 2 |
| 31 Mar 25 | 37 | -24 | 34 | 2 |
| 31 Dec 24 | 32 | -27 | 36 | 2 |
| 30 Sep 24 | 27 | -32 | 38 | 2 |
| 30 Jun 24 | 21 | -36 | 40 | 2 |
| 31 Mar 24 | 17 | -35 | 39 | 2 |
| 31 Dec 23 | 13 | -33 | 38 | 2 |
| 30 Sep 23 | 10 | -40 | 37 | 1 |
| 30 Jun 23 | 7 | -47 | 36 | 0 |
| 31 Mar 23 | 6 | -49 | 35 | 1 |
| 31 Dec 22 | 5 | -50 | 34 | 1 |
| 30 Sep 22 | 5 | -39 | 32 | 1 |
| 30 Jun 22 | 4 | -30 | 32 | 0 |
| 31 Mar 22 | 3 | -29 | 30 | 1 |
| 31 Dec 21 | 2 | -27 | 27 | 1 |
| 30 Sep 21 | 2 | -22 | 20 | 3 |
| 30 Jun 21 | 3 | -18 | 14 | 5 |
| 31 Mar 21 | 9 | -11 | 13 | 4 |
| 31 Dec 20 | 14 | -4 | 12 | 4 |
| 30 Sep 20 | 13 | -3 | 11 | 3 |
| 30 Jun 20 | 11 | -2 | 10 | 2 |
| 31 Mar 20 | 6 | -6 | 9 | 3 |
| 31 Dec 19 | 1 | -12 | 9 | 3 |
| 30 Sep 19 | 8 | -4 | 10 | 4 |
| 30 Jun 19 | 15 | 3 | 12 | 4 |
| 31 Mar 19 | 15 | 0 | 14 | 5 |
| 31 Dec 18 | 15 | -2 | 16 | 5 |
| 30 Sep 18 | 8 | -13 | 18 | 6 |
| 30 Jun 18 | 1 | -24 | 20 | 6 |
| 31 Mar 18 | 1 | -26 | 22 | 7 |
| 31 Dec 17 | 1 | -26 | 23 | 6 |
| 30 Sep 17 | 1 | -24 | 20 | 5 |
| 30 Jun 17 | 0 | -21 | 18 | 4 |
| 31 Mar 17 | 0 | -19 | 15 | 3 |
| 31 Dec 16 | 0 | -19 | 13 | 3 |
| 30 Sep 16 | 0 | -12 | 11 | 4 |
| 30 Jun 16 | 0 | -4 | 8 | 6 |
| 31 Mar 16 | 0 | -19 | 5 | 7 |
| 31 Dec 15 | 0 | -35 | 2 | 8 |
| 30 Sep 15 | 0 | -41 | 2 | 6 |
| 30 Jun 15 | 0 | -49 | 2 | 4 |
Quality Earnings: STX is currently unprofitable.
Growing Profit Margin: STX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STX is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare STX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (33.7%).
Return on Equity
High ROE: STX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 17:51 |
| End of Day Share Price | 2026/06/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shield Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |